Fortress Biotech Inc
FBIO3.670USD
+0.110+3.09%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
109.19MMarket Cap
LossP/E TTM
More Details of Fortress Biotech Inc Company
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).
Company Info
Ticker SymbolFBIO
Company nameFortress Biotech Inc
IPO dateNov 17, 2011
CEODr. Lindsay A. Rosenwald, M.D.
Number of employees101
Security typeOrdinary Share
Fiscal year-endNov 17
Address1111 Kane Concourse
CityBAY HARBOR ISLANDS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33154
Phone17816524500
Websitehttps://www.fortressbiotech.com/
Ticker SymbolFBIO
IPO dateNov 17, 2011
CEODr. Lindsay A. Rosenwald, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.11M
-27.60%
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
1.80M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
27.44K
--
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
10.89K
--
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Mr. Malcolm I. Hoenlein, Ph.D.
Mr. Malcolm I. Hoenlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jimmie Harvey, Jr., M.D.
Dr. Jimmie Harvey, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
Mr. Kevin L. Lorenz, J.D.
Mr. Kevin L. Lorenz, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board, President, Chief Executive Officer
Executive Chairman of the Board, President, Chief Executive Officer
4.11M
-27.60%
Mr. Michael S. Weiss, J.D.
Mr. Michael S. Weiss, J.D.
Executive Vice Chairman - Strategic Development, Director
Executive Vice Chairman - Strategic Development, Director
1.80M
--
Mr. Dov Klein, CPA
Mr. Dov Klein, CPA
Independent Director
Independent Director
27.44K
--
Mr. David Jin
Mr. David Jin
Chief Financial Officer and Head of Corporate Development
Chief Financial Officer and Head of Corporate Development
10.89K
--
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Chief Strategy Officer
Chief Strategy Officer
5.22K
--
Mr. J. Jay Lobell, J.D.
Mr. J. Jay Lobell, J.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Wed, Apr 2
Currency: USDUpdated: Wed, Apr 2
FY2023
FY2023Q4
FY2022
FY2022Q4
FY2021
FY2019
By BusinessUSD
Name
Revenue
Proportion
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Targadox®
3.20M
3.79%
Exelderm®
2.40M
2.83%
Ximino®
287.00K
0.34%
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Rosenwald (Lindsay A)
13.82%
Weiss (Michael S)
6.05%
Summit Financial, LLC
3.41%
The Vanguard Group, Inc.
2.87%
Kestra Advisory Services, LLC
1.12%
Other
72.73%
Shareholders
Shareholders
Proportion
Rosenwald (Lindsay A)
13.82%
Weiss (Michael S)
6.05%
Summit Financial, LLC
3.41%
The Vanguard Group, Inc.
2.87%
Kestra Advisory Services, LLC
1.12%
Other
72.73%
Shareholder Types
Shareholders
Proportion
Individual Investor
20.97%
Investment Advisor
12.88%
Investment Advisor/Hedge Fund
1.86%
Hedge Fund
1.71%
Research Firm
0.11%
Venture Capital
0.08%
Bank and Trust
0.04%
Other
62.35%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
118
9.92M
33.55%
-5.95M
2025Q1
127
12.83M
43.44%
-3.02M
2024Q4
132
11.23M
43.27%
-798.32K
2024Q3
135
10.32M
40.34%
-1.08M
2024Q2
142
8.74M
39.80%
-2.02M
2024Q1
167
8.10M
41.60%
-2.26M
2023Q4
174
9.36M
62.75%
+4.57M
2023Q3
176
4.38M
269.99%
-553.11K
2023Q2
183
4.49M
52.62%
-453.66K
2023Q1
193
4.84M
60.24%
+13.06K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Rosenwald (Lindsay A)
4.11M
13.9%
-1.57M
-27.60%
Apr 17, 2025
Weiss (Michael S)
1.80M
6.09%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
752.55K
2.54%
+127.50K
+20.40%
Mar 31, 2025
Kestra Advisory Services, LLC
292.48K
0.99%
+66.25K
+29.28%
Mar 31, 2025
Nantahala Capital Management, LLC
325.52K
1.1%
+200.00K
+159.34%
Mar 31, 2025
PVG Asset Management Corporation
472.22K
1.6%
+85.93K
+22.24%
Mar 31, 2025
Shikiar Asset Management, Inc.
235.97K
0.8%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
237.53K
0.8%
+33.00K
+16.13%
Mar 31, 2025
Envestnet Asset Management, Inc.
267.91K
0.91%
+28.31K
+11.82%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Date
Type
Ratio
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
Oct 09, 2023
Merger
15→1
